Palvella Therapeutics (PVLA) Change in Receivables (2014 - 2025)

Palvella Therapeutics' (PVLA) quarterly Change in Receivables came in at -$29000.0 in Q4 2025, up 91.9% on a QoQ basis from -$358000.0 in Q1 2025.

Palvella Therapeutics (PVLA) Change in Receivables (2014 - 2025) Analysis & Trends

Palvella Therapeutics (PVLA) has 4 years of Change in Receivables data on file, last reported at -$29000.0 in Q4 2025.

On a quarterly basis, Change in Receivables changed N/A year-over-year to -$29000.0 in Q4 2025; TTM through Dec 2025 was -$387000.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$387000.0, changed N/A from the prior year.
Change in Receivables for Q4 2025 stood at -$29000.0, up from -$358000.0 in the prior quarter.
Over the last five years, Change in Receivables for PVLA reached as high as -$29000.0 in Q4 2025 and fell as low as -$358000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	75.30 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	2.84 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-39.80 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-1.20 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Palvella Therapeutics	318.78 Mn	56.92 Mn	-	-

Download Data